Bimekizumab

Bimekizumab (pronounced as bi-me-ki-zu-mab) is a humanized monoclonal antibody designed for the treatment of autoimmune diseases.

Etymology

The name "Bimekizumab" is derived from the International Nonproprietary Names (INN), where "bi-" refers to its biological origin, "-mab" indicates it is a monoclonal antibody, "-eki-" is a substem used for immunomodulating monoclonal antibodies, and "zu" is a random infix.

Pharmacology

Bimekizumab is a monoclonal antibody that selectively inhibits both interleukin 17A and interleukin 17F, two key cytokines driving inflammatory processes. By targeting and neutralizing these cytokines, Bimekizumab can help to control the inflammatory response that leads to the symptoms of autoimmune diseases.

Clinical Uses

Bimekizumab is currently being investigated for its potential use in several autoimmune diseases, including psoriasis, psoriatic arthritis, and ankylosing spondylitis.

Related Terms

• Monoclonal Antibody
• Interleukin 17A
• Interleukin 17F
• Autoimmune Diseases
• Psoriasis
• Psoriatic Arthritis
• Ankylosing Spondylitis

See Also

• List of Monoclonal Antibodies
• List of Autoimmune Diseases

External links

• Medical encyclopedia article on Bimekizumab
• Wikipedia's article - Bimekizumab

This WikiMD article is a stub. You can help make it a full article.

---

Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski